NEOSURF SUSPENSION

País: Canadà

Idioma: anglès

Font: Health Canada

ingredients actius:

PHOSPHOLIPID; SURFACTANT-ASSOCIATED PROTEINS SP-B AND SP-C

Disponible des:

CIPLA LTD

Codi ATC:

R07AA02

Designació comuna internacional (DCI):

NATURAL PHOSPHOLIPIDS

Dosis:

27MG; 500MCG

formulario farmacéutico:

SUSPENSION

Composición:

PHOSPHOLIPID 27MG; SURFACTANT-ASSOCIATED PROTEINS SP-B AND SP-C 500MCG

Vía de administración:

INTRATRACHEAL

Unidades en paquete:

100

tipo de receta:

Ethical

Área terapéutica:

PULMONARY SURFACTANTS

Resumen del producto:

Active ingredient group (AIG) number: 0252489001; AHFS:

Estat d'Autorització:

APPROVED

Data d'autorització:

2006-11-20

Fitxa tècnica

_NEOSURF (bovine lipid extract surfactant) Product Monograph _
_Page 1 of 19_
PRODUCT MONOGRAPH
NEOSURF
(bovine lipid extract surfactant)
Suspension for Intratracheal Instillation
27 mg phospholipid/mL
THERAPEUTIC CLASSIFICATION
Lung surfactant (bovine)
Manufactured by:
CIPLA LTD.
Mumbai Central
Mumbai 400 008, India
Distributed by:
BLES Biochemicals Inc.
60 Pacific Court, Unit 8
London, Ontario, Canada N5V 3K4
DATE OF AUTHORIZATION: MARCH 16, 2012
CONTROL NO.: 152500
PR
_NEOSURF (bovine lipid extract surfactant) Product Monograph _
_Page 2 of 19_
TABLE OF CONTENTS
THERAPEUTIC CLASSIFICATION
......................................................................................................
3
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
3
SUMMARY PRODUCT INFORMATION
.............................................................................3
DESCRIPTION
........................................................................................................................3
INDICATIONS AND CLINICAL
USE...................................................................................3
CONTRAINDICATIONS
........................................................................................................3
WARNINGS AND
PRECAUTIONS.......................................................................................4
ADVERSE
REACTIONS.........................................................................................................5
DRUG
INTERACTIONS.........................................................................................................9
DOSAGE AND
ADMINISTRATION.....................................................................................9
OVERDOSAGE
.....................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
.................................................................12
STORAGE AND
STABILITY...........................